세계의 성감염증(STI) 및 질염 PCR 검사 시장 규모, 점유율, 동향 분석 보고서 : 증상별, 검사 종류별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

STI And Vaginitis PCR Testing Market Trends:

The global STI and vaginitis PCR testing market size was estimated at USD 660.97 million in 2024 and is projected to reach USD 1,111.9 million by 2030, growing at a CAGR of 9.21% from 2025 to 2030. This is attributed to the rising global incidence of sexually transmitted and vaginal infections.

Increasing public awareness of sexual and reproductive health, and the increasing preference for highly sensitive molecular diagnostic methods such as PCR testing, significantly drive the market expansion. According to CDC data in 2023, more than 2.4 million cases of syphilis, gonorrhea, and chlamydia were diagnosed and reported in the U.S. This total comprised over 209,000 cases of syphilis, more than 600,000 cases of gonorrhea, and upwards of 1.6 million cases of chlamydia. Additionally, expanding access to at-home testing kits, technological advancements in multiplex PCR assays, and greater investment in public health infrastructure are expected to further drive market growth over the forecast period.

Developing regions are witnessing particularly sharp increases in STIs and vaginitis prevalence, primarily due to inadequate healthcare infrastructure and limited screening programs. Urbanization, migration, and high-risk sexual practices contribute to this rising disease burden. These factors increase the need for accessible, sensitive diagnostic tools capable of handling high sample volumes and delivering reliable results. With its ability to detect low levels of pathogen DNA or RNA, PCR testing meets these demands effectively and is increasingly adopted in public health screening initiatives across such regions.

Regulatory approvals for new PCR diagnostic tests significantly impact the growth trajectory of the STI and vaginitis PCR testing industry. Obtaining approvals from authorities such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and other regional bodies facilitates faster market access and builds confidence among healthcare providers. Recent approvals of multiplex PCR kits that detect multiple STIs and vaginitis-causing pathogens in a single test streamline the diagnostic process, enhancing clinical workflow efficiency. These authorized products set quality and performance benchmarks that encourage widespread adoption.

Global STI And Vaginitis PCR Testing Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For this report, Grand View Research has segmented the global STI and vaginitis PCR testing market report based on condition, test type, end-use, and region:

• Condition Outlook (Revenue, USD Million, 2018 - 2030)
• Sexually Transmitted Infections (STIs)
  • Chlamydia
  • Gonorrhea
  • Trichomoniasis
  • Herpes Simplex Virus (HSV-1 & HSV-2)
  • Human Papillomavirus (HPV)
  • Syphilis
  • Other
• Vaginal Infections
  • Bacterial Vaginosis
  • Vulvovaginal Candidiasis
  • Other
• Test type Outlook (Revenue, USD Million, 2018 - 2030)
• STI PCR Panels
• Vaginitis PCR Panels
• End-use Outlook (Revenue, USD Million, 2018 - 2030)
• Hospitals and Clinics
• Diagnostic Laboratories
• Homecare/At-home Testing
• Others
• Regional Outlook (Revenue, USD Million, 2018 - 2030)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Portugal
  • Hungary
  • Turkey
  • Slovenia
  • Norway
  • Denmark
  • Sweden
  • Estonia
  • Finland
  • Latvia
  • Lithuania
  • Poland
  • Russia
  • Ukraine
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
  • Malaysia
  • Indonesia
  • Vietnam
  • Taiwan
  • Mongolia
• Latin America
  • Brazil
  • Argentina
  • Colombia
  • Chile
  • Ecuador
  • Peru
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Kuwait
  • Africa

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Condition
  • 1.2.2. Test Type
  • 1.2.3. End Use
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
• 1.5. Primary research
  • 1.5.1. Details of primary research
    • 1.5.1.1. Data for primary interviews in North America
    • 1.5.1.2. Data for primary interviews in Europe
    • 1.5.1.3. Data for primary interviews in Asia Pacific
    • 1.5.1.4. Data for primary interviews in Latin America
    • 1.5.1.5. Data for Primary interviews in MEA
  • 1.5.2. Information or Data Analysis
  • 1.5.3. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Condition outlook
  • 2.2.2. Test Type Outlook
  • 2.2.3. End Use Outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. STI and vaginitis PCR testing Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising prevalence of STIs and vaginitis infections fuels market demand
    • 3.2.1.2. Regulatory approvals accelerate market adoption and innovation
    • 3.2.1.3. Technological advancements enhance accuracy and accessibility of PCR testing
    • 3.2.1.4. Growing awareness and screening programs boost early diagnosis rates
• 3.3. Market Restraint Analysis
  • 3.3.1.1. High cost of PCR testing limits market penetration
  • 3.3.1.2. Lack of skilled personnel and infrastructure challenges
  • 3.3.1.3. Privacy concerns and social stigma affect testing rates
• 3.4. STI and vaginitis PCR testing Market Analysis Tools
  • 3.4.1. Industry Analysis - Porter's
  • 3.4.2. PESTEL Analysis

Chapter 4. STI and vaginitis PCR testing Market: Condition Estimates & Trend Analysis

• 4.1. Condition Market Share, 2024 & 2030
• 4.2. Segment Dashboard
• 4.3. Global STI and vaginitis PCR testing Market by Condition Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.4.1. Sexually Transmitted Infections (STIs)
    • 4.4.1.1. STI's market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.2. Chlamydia
      • 4.4.1.2.1. Chlamydia market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.3. Gonorrhea
      • 4.4.1.3.1. Gonorrhea market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.4. Trichomoniasis
      • 4.4.1.4.1. Trichomoniasis market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.5. Herpes Simplex Virus (HSV-1 & HSV-2)
      • 4.4.1.5.1. HSV market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.6. Human Papillomavirus (HPV)
      • 4.4.1.6.1. HPV market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.7. Syphilis
      • 4.4.1.7.1. Syphilis market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.8. Other
      • 4.4.1.8.1. Other market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.2. Vaginal Infections
    • 4.4.2.1. Vaginal infections market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2.2. Bacterial Vaginosis
      • 4.4.2.2.1. Bacterial Vaginosis market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2.3. Vulvovaginal Candidiasis
      • 4.4.2.3.1. Vulvovaginal Candidiasis market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2.4. Other
    • 4.4.2.5. Other market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. STI and vaginitis PCR testing Market: Test Type Estimates & Trend Analysis

• 5.1. Test Type Market Share, 2024 & 2030
• 5.2. Segment Dashboard
• 5.3. Global STI and vaginitis PCR testing Market by Test Type Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.4.1. STI PCR Panels
    • 5.4.1.1. STI PCR panels market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.2. Vaginitis PCR Panels
    • 5.4.2.1.1. Vaginitis PCR panels market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. STI and vaginitis PCR testing Market: End use Estimates & Trend Analysis

• 6.1. End Use Market Share, 2024 & 2030
• 6.2. Segment Dashboard
• 6.3. Global STI and vaginitis PCR testing Market by End Use Outlook
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.4.1. Hospitals and Clinics
    • 6.4.1.1. Hospitals and Clinics market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.2. Diagnostic Laboratories
    • 6.4.2.1. Diagnostic Laboratories market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.3. Homecare/At-home Testing
    • 6.4.3.1. Homecare/At-home Testing market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.4. Others
    • 6.4.4.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. STI and Vaginitis PCR Testing Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2024 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Global Regional Market Snapshot
• 7.4. Market Size, & Forecasts, Trend Analysis, 2018 to 2030:
• 7.5. North America
  • 7.5.1. U.S.
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.2. Canada
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.3. Mexico
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Europe
  • 7.6.1. UK
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.2. Germany
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.3. France
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Regulatory framework/ reimbursement structure
    • 7.6.3.3. Competitive scenario
    • 7.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.4. Italy
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Regulatory framework/ reimbursement structure
    • 7.6.4.3. Competitive scenario
    • 7.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.5. Spain
    • 7.6.5.1. Key country dynamics
    • 7.6.5.2. Regulatory framework/ reimbursement structure
    • 7.6.5.3. Competitive scenario
    • 7.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.6. Norway
    • 7.6.6.1. Key country dynamics
    • 7.6.6.2. Regulatory framework/ reimbursement structure
    • 7.6.6.3. Competitive scenario
    • 7.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.7. Sweden
    • 7.6.7.1. Key country dynamics
    • 7.6.7.2. Regulatory framework/ reimbursement structure
    • 7.6.7.3. Competitive scenario
    • 7.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.8. Denmark
    • 7.6.8.1. Key country dynamics
    • 7.6.8.2. Regulatory framework/ reimbursement structure
    • 7.6.8.3. Competitive scenario
    • 7.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.9. Portugal
    • 7.6.9.1. Key country dynamics
    • 7.6.9.2. Regulatory framework/ reimbursement structure
    • 7.6.9.3. Competitive scenario
    • 7.6.9.4. Portugal market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.10. Turkey
    • 7.6.10.1. Key country dynamics
    • 7.6.10.2. Regulatory framework/ reimbursement structure
    • 7.6.10.3. Competitive scenario
    • 7.6.10.4. Turkey market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.11. Slovenia
    • 7.6.11.1. Key country dynamics
    • 7.6.11.2. Regulatory framework/ reimbursement structure
    • 7.6.11.3. Competitive scenario
    • 7.6.11.4. Slovenia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.12. Estonia
    • 7.6.12.1. Key country dynamics
    • 7.6.12.2. Regulatory framework/ reimbursement structure
    • 7.6.12.3. Competitive scenario
    • 7.6.12.4. Estonia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.13. Sweden
    • 7.6.13.1. Key country dynamics
    • 7.6.13.2. Regulatory framework/ reimbursement structure
    • 7.6.13.3. Competitive scenario
    • 7.6.13.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.14. Finland
    • 7.6.14.1. Key country dynamics
    • 7.6.14.2. Regulatory framework/ reimbursement structure
    • 7.6.14.3. Competitive scenario
    • 7.6.14.4. Finland market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.15. Latvia
    • 7.6.15.1. Key country dynamics
    • 7.6.15.2. Regulatory framework/ reimbursement structure
    • 7.6.15.3. Competitive scenario
    • 7.6.15.4. Latvia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.16. Lithuania
    • 7.6.16.1. Key country dynamics
    • 7.6.16.2. Regulatory framework/ reimbursement structure
    • 7.6.16.3. Competitive scenario
    • 7.6.16.4. Lithuania market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.17. Poland
    • 7.6.17.1. Key country dynamics
    • 7.6.17.2. Regulatory framework/ reimbursement structure
    • 7.6.17.3. Competitive scenario
    • 7.6.17.4. Poland market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.18. Russia
    • 7.6.18.1. Key country dynamics
    • 7.6.18.2. Regulatory framework/ reimbursement structure
    • 7.6.18.3. Competitive scenario
    • 7.6.18.4. Russia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.19. Ukraine
    • 7.6.19.1. Key country dynamics
    • 7.6.19.2. Regulatory framework/ reimbursement structure
    • 7.6.19.3. Competitive scenario
    • 7.6.19.4. Ukraine market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. Asia Pacific
  • 7.7.1. Japan
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.2. China
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.3. India
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.4. Australia
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.5. South Korea
    • 7.7.5.1. Key country dynamics
    • 7.7.5.2. Regulatory framework/ reimbursement structure
    • 7.7.5.3. Competitive scenario
    • 7.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.6. Thailand
    • 7.7.6.1. Key country dynamics
    • 7.7.6.2. Regulatory framework/ reimbursement structure
    • 7.7.6.3. Competitive scenario
    • 7.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.7. Malaysia
    • 7.7.7.1. Key country dynamics
    • 7.7.7.2. Regulatory framework/ reimbursement structure
    • 7.7.7.3. Competitive scenario
    • 7.7.7.4. Malaysia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.8. Indonesia
    • 7.7.8.1. Key country dynamics
    • 7.7.8.2. Regulatory framework/ reimbursement structure
    • 7.7.8.3. Competitive scenario
    • 7.7.8.4. Indonesia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.9. Vietnam
    • 7.7.9.1. Key country dynamics
    • 7.7.9.2. Regulatory framework/ reimbursement structure
    • 7.7.9.3. Competitive scenario
    • 7.7.9.4. Vietnam market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.10. Taiwan
    • 7.7.10.1. Key country dynamics
    • 7.7.10.2. Regulatory framework/ reimbursement structure
    • 7.7.10.3. Competitive scenario
    • 7.7.10.4. Taiwan market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.11. Thailand
    • 7.7.11.1. Key country dynamics
    • 7.7.11.2. Regulatory framework/ reimbursement structure
    • 7.7.11.3. Competitive scenario
    • 7.7.11.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.12. Mongolia
    • 7.7.12.1. Key country dynamics
    • 7.7.12.2. Regulatory framework/ reimbursement structure
    • 7.7.12.3. Competitive scenario
    • 7.7.12.4. Mongolia market estimates and forecasts 2018 to 2030 (USD Million)
• 7.8. Latin America
  • 7.8.1. Brazil
    • 7.8.1.1. Key country dynamics
    • 7.8.1.2. Regulatory framework/ reimbursement structure
    • 7.8.1.3. Competitive scenario
    • 7.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8.2. Argentina
    • 7.8.2.1. Key country dynamics
    • 7.8.2.2. Regulatory framework/ reimbursement structure
    • 7.8.2.3. Competitive scenario
    • 7.8.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8.3. Colombia
    • 7.8.3.1. Key country dynamics
    • 7.8.3.2. Regulatory framework/ reimbursement structure
    • 7.8.3.3. Competitive scenario
    • 7.8.3.4. Colombia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8.4. Chile
    • 7.8.4.1. Key country dynamics
    • 7.8.4.2. Regulatory framework/ reimbursement structure
    • 7.8.4.3. Competitive scenario
    • 7.8.4.4. Chile market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8.5. Ecuador
    • 7.8.5.1. Key country dynamics
    • 7.8.5.2. Regulatory framework/ reimbursement structure
    • 7.8.5.3. Competitive scenario
    • 7.8.5.4. Ecuador market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8.6. Peru
    • 7.8.6.1. Key country dynamics
    • 7.8.6.2. Regulatory framework/ reimbursement structure
    • 7.8.6.3. Competitive scenario
    • 7.8.6.4. Peru market estimates and forecasts 2018 to 2030 (USD Million)
• 7.9. MEA
  • 7.9.1. Africa
    • 7.9.1.1. Key country dynamics
    • 7.9.1.2. Regulatory framework/ reimbursement structure
    • 7.9.1.3. Competitive scenario
    • 7.9.1.4. Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9.2. Saudi Arabia
    • 7.9.2.1. Key country dynamics
    • 7.9.2.2. Regulatory framework/ reimbursement structure
    • 7.9.2.3. Competitive scenario
    • 7.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9.3. UAE
    • 7.9.3.1. Key country dynamics
    • 7.9.3.2. Regulatory framework/ reimbursement structure
    • 7.9.3.3. Competitive scenario
    • 7.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9.4. Kuwait
    • 7.9.4.1. Key country dynamics
    • 7.9.4.2. Regulatory framework/ reimbursement structure
    • 7.9.4.3. Competitive scenario
    • 7.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. Key company market share analysis, 2024
  • 8.3.2. BD
    • 8.3.2.1. Company overview
    • 8.3.2.2. Financial performance
    • 8.3.2.3. Product benchmarking
    • 8.3.2.4. Strategic initiatives
  • 8.3.3. F. Hoffmann-La Roche Ltd.
    • 8.3.3.1. Company overview
    • 8.3.3.2. Financial performance
    • 8.3.3.3. Product benchmarking
    • 8.3.3.4. Strategic initiatives
  • 8.3.4. Hologic, Inc.
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. Abbott
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Product benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. Danaher Corporation (Cepheid)
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Product benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Seegene Inc.
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Product benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. bioMerieux (BioFire Diagnostics)
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Product benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. QIAGEN
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Product benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. Thermo Fisher Scientific, Inc.
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Product benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. DiaSorin S.p.A (Luminex)
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Product benchmarking
    • 8.3.11.4. Strategic initiatives
  • 8.3.12. Sansure Biotech Inc.
    • 8.3.12.1. Company overview
    • 8.3.12.2. Financial performance
    • 8.3.12.3. Product benchmarking
    • 8.3.12.4. Strategic initiatives
  • 8.3.13. R-Biopharm AG
    • 8.3.13.1. Company overview
    • 8.3.13.2. Financial performance
    • 8.3.13.3. Product benchmarking
    • 8.3.13.4. Strategic initiatives
  • 8.3.14. altona Diagnostics GmbH
    • 8.3.14.1. Company overview
    • 8.3.14.2. Financial performance
    • 8.3.14.3. Product benchmarking
    • 8.3.14.4. Strategic initiatives
  • 8.3.15. CERTEST BIOTEC
    • 8.3.15.1. Company overview
    • 8.3.15.2. Financial performance
    • 8.3.15.3. Product benchmarking
    • 8.3.15.4. Strategic initiatives